

Financial Tear Sheet

Primary IR Contact

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com
(mailto:invest@ctibiopharma.com)

Transfer Agent

Computershare

Mail:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078

Overnight Delivery:
Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States of America

T: 312-588-4187
F: 312-601-4332
www.Computershare.com
(http://www.computershare.com)

Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$2.26**

Change
(%) ▼ 1.73 (43.36%)

Volume 5,141,662

52 Week Low \$2.45

Market Cap \$231,343,803

Rolling EPS -0.66

PE Ratio 0

Shares Outstanding 57,980,903

Data as of 07/18/18 4:00 p.m. ET



Recent Headlines & Events

Jul 18, 2018 - 7:00 a.m.

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2358781)

There are currently no events scheduled.

Jul 09, 2018 - 7:00 a.m.

Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2357334)

Jul 02, 2018 - 7:00 a.m.

CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2356742)

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	103	152.23	67.1	38,913,526
Mutual Fund	46	45.05	17.7	10,238,678
Insider *	7	1.64	0.7	412,905

**Insider values reflect direct beneficial ownership.*

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
BVF Partners L.P.	6,929,690	12.0	-1,666,667	03/31/18
Stonepine Capital Management, LLC	5,141,746	8.9	3,306,908	03/31/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	03/31/18
New Enterprise Associates (NEA)	3,750,000	6.5	3,750,000	03/31/18
Franklin Advisers, Inc.	3,472,300	6.0	3,472,300	03/31/18
The Vanguard Group, Inc.	2,152,864	3.7	1,301,983	03/31/18
Great Point Partners, LLC	1,687,020	2.9	1,687,020	03/31/18
Fidelity Management & Research Company	1,400,000	2.4	1,400,000	03/31/18
NB Public Equity Komplementar ApS	1,356,635	2.3	90,000	12/31/16
Sphera Funds Management Ltd.	833,633	1.4	0	03/31/18

Data provided by Nasdaq. Minimum 15 minutes delayed.